Table 1.

CMR characteristics for control rats, imatinib and placebo treated rats

	Control (n = 5)	Imatinib (n = 10*)	Placebo (n = 9)	p-value Control vs Placebo	p-value Imatinib vs Placebo
Heart rate (bpm)	370.6 ± 36.2	372.6 ± 41.6	357.7 ± 35.5	0.53	0.41
LVEDV (mL)	0.32 ± 0.01	0.30 ± 0.04	0.28 ± 0.04	0.040	0.48
LVESV (mL)	0.13 ± 0.01	0.12 ± 0.03	0.13 ± 0.03	0.88	0.55
SV (mL)	0.20 ± 0.02	0.18 ± 0.04	0.16 ± 0.04	0.068	0.30
CO (mL/min)	68 ± 8.4	63 ± 13.4	54 ± 13.3	0.064	0.18
LVEF (%)	60.3 ± 4.2	59.0 ± 8.4	54.0 ± 9.8	0.20	0.24
GCS (%)	− 38.0 ± 2.2	− 35.4 ± 7.5	− 31.3 ± 7.5	0.078	0.24
GLS (%)	− 22.0 ± 1.3	− 16.6 ± 3.1	− 15.7 ± 3.3	< 0.001	0.54
LV mass (mg)	378 ± 8	424 ± 67	413 ± 35	0.017	0.67
Infarct size (%LV)	N.a	12.6 ± 8.8	25.6 ± 9.3	N.a	0.008
Remote T2 values (ms)	20.2 ± 2.6	19.4 ± 4.8	19.3 ± 5.5	0.74	0.97
Infarct T2 values (ms)	N.a	37.9 ± 12.0	41.0 ± 16.0	N.a	0.65

Numbers can be written down in bold (without italics) to highlight the differences between the groups

Data is presented as mean ± SD, assessed by independent-samples T test

Bpm beats per minute, CO cardiac output, EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, GCS global circumferential strain, GLS global longitudinal strain, LV left ventricle, N.a not applicable, SV stroke volume

*n = 10 for cardiac function, n = 9 for infarct size and T2 values